icc2024 – 33rd International Congress of Antimicrobial Chemotherapy

Aula Abbara

Imperial College NHS Healthcare Trust, London,
UK

Murat Akova

Hacettepe University,
Türkiye

Arzu Akşit İlki

Marmara University,
Türkiye

Emine Alp Mese

Ankara Yıldırım Beyazıt University,
Türkiye

Fatma Amer

Zagazg Faculty of Medicine,
Egypt

Anucha Apisarnthanarak

Thammasat University Hospital,
Thailand

Sevtap Arikan-Akdagli

Hacettepe University,
Türkiye

Sohret Aydemir

Ege University,
Türkiye

Özlem Kurt Azap

Başkent University,
Türkiye

April Baller

World Health Organization,
Switzerland

Emma Birnie

Center for Experimental Molecular Medicine
the Netherlands

Roger Brüggemann

Radboud University Medical Center,
Netherlands

Yasemin Çağ

Istanbul Medeniyet University,
Türkiye

Aslihan Candevir

Çukurova University,
Türkiye

Krystyna Dąbrowska

Polish Academy of Sciences,
Poland

Ener Cagri Dinleyici

Eskisehir Osmangazi University,
Türkiye

Mine Durusu Tanriover

Hacettepe University,
Türkiye

Androulla Efstratiou

UK Health Security Agency,
UK

Adrian Egli

University of Zrich
Switzerland

Rehab El-Sokkary

Zagazig University,
Egypt

Hakan Erdem

Turkish Health Sciences University,
Türkiye

Önder Ergönül

Koç University
Türkiye

Ozgen Eser

Hacettepe University,
Türkiye

Antoine Abou Fayad

American University of Beirut,
Spain

Richard Ferrer

Autonomous University of Barcelona,
Spain

Evangelos Giamarellos-Borboulis

National and Kapodistrian University of Athens,
Greece

Deniz Gokengin

Ege University,
Türkiye

Nelesh Govender

University of the Witwatersrand
South Africa

Aycan Gundogdu

Erciyes University,
Türkiye

Bulent Gurler

Hospital Inf. and Sterilisation&Disenfection aspects ,
Türkiye

Rana Hajjeh

World Health Organization- EMRO,
Egypt

Ufuk Hasdemir

Marmara University,
Türkiye

Hans Hellmuth Hirsch

University of Basel,
Switzerland

Po-Ren Hsueh

China Medical University Hospital,
Taiwan

Jakko Van Ingen

Radboud University Medical Center,
the Netherlands

Jon Iredell

Westmead Institute for Medical Research,
Australia

Ahmet Çağkan İnkaya

Hacettepe University,
Türkiye

David Jenkins

University Hospitals of Leicester NHS Trust,
UK

Gunnar Kahlmeter

Clinical microbiology and EUCAST Development Laboratory, Växjö,
Sweden

Zeynep Ceren Karahan

Ankara University,
Türkiye

Onur Karatuna

EUCAST Development Laboratory, Växjö,
Sweden

Şiran Keske

American Hospital
Türkiye

Martin Kiernan

Richard Wells Research Centre, University of West London,
UK

Tanil Kocagoz

Acibadem Mehmet Ali Aydınlar University,
Türkiye

Volkan Korten

Marmara University, Istanbul, Turkey,
Türkiye

Ozgur Kurt

Acıbadem University,
Türkiye

Cornelia Lass-Flörl

Institut Pasteur,
France

Marc Lecuit

Institut Pasteur,
France

Jian Li

Monash University,
Malaysia

David Lye

National Centre for Infectious Diseases,
Singapore

Edwin David McIntosh

Honorary Clinical Senior Lecturer Imperial College London
UK

Hiroshige Mikamo

Aichi Medical University
Japan

Andrew Miller

Elsevier, Oxford,
UK

Yin Mo

National University Hospital,
Singapore

Muharrem Muftuoglu

MD Anderson Cancer Center,
USA

Jomana Musmar

Deputy Director of Strategic Initiatives, OIDP
Executive Director, PACCARB
USA

Miki Nagao

Kyoto University Hospital,
Japan

Kristina Osbjer

International Centre for Antimicrobial Resistance Solutions,
Sweden

David Paterson

National University of Singapore,
Singapore

Philippe Pérot

Institut Pasteur, Paris,
France

Tom van der Poll

Amsterdam University Medical Center,
the Netherlands

Mario Ramirez

Faculdade de Medicina, Universidade de Lisboa,
Portugal

Nesrine Rizk

American University of Beirut Medical Center,
Lebanon

Alfonso J. Rodriguez-Morales

Fundacion Universitaria Autonoma de las Americas,
Colombia

Gian Maria Rossolini

University of Florence,
Italy

Kordo Saeed

University Hospitals Southampton NHS Foundation Trust,
UK

Nuran Salman

Istanbul University,
Türkiye

Ayca Arzu Sayiner

Dokuz Eylul University,
Türkiye

Juliëtte Severin

Erasmus MC University Medical Center, Rotterdam
the Netherlands

Souha Kanj

American University of Beirut Medical Center,
Lebanon

Jeroen Schouten

ESCMID Study Group of Antimicrobial Stewardship,
the Netherlands

Robert Skov

Statens Serum Institut, Copenhagen,
Denmark

Stefania Stefani

University of Catania,
Italy

Paul Ananth Tambyah

National University of Singapore,
Singapore

Alpaslan Tanoglu

Bahçeşehir University,
Türkiye

Fred C. Tenover

University of Dayton,
USA

Ozlem Tureci

Co-Founder and Chief Medical Officer of BioNTech,
Germany

Aysegul Ulu Kilic

Erciyes University,
Türkiye

Serhat Unal

Hacettepe University,
Türkiye

Omrum Uzun

Hacettepe University,
Türkiye

Margreet Vos

ErasmusMC Rotterdam,
the Netherlands

Andreas Voss

International Society of Antimicrobial Chemotherapy (ISAC),
the Netherlands

Timothy Walsh

University of Oxford,
UK

Heiman Wertheim

Radboud University Medical Center,
the Netherlands

Sebastian Wicha

University of Hamburg,
Germany

Andreas Widmer

Swiss National Center for Infection Prevention,
Switzerland

Ata Nevzat Yalcin

Akdeniz University,
Türkiye

Yazdan Yazdanpanah

ANRS Maladies Infectieuses Emergentes,
France

Monkez Yousif

Faculty of Medicine, Zagazig University,
Egypt

Abstract	Presenter	Abstract Title
200	Eftychia Eirini Maria Gourdoupari	Prognostic cut-off values of neutrofil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for COVID-19: a case-control retrospective single-center study
584	Şiran Keske	Insights from One of the Largest COVID-19 Cohorts: A Detailed Analysis of Risk Factors, Mortality Predictors, and Vaccine Efficacy in Istanbul
145	Arzuhan Buyuker	Evaluation of The Anti-Viral Response Against SARS-CoV-2 Omicron Variant Appeared In The First Half of 2024 in Healthcare Workers Using In Vitro Cell Culture Model
539	Eda Alp	Association of Hepatitis-B virus infection status with survival and treatment response in non-small cell lung cancer patients on anti-pd-1/pd-l1 therapy
668	Nida Özcan	Changes in Hepatitis C Virus Genotype Distribution in Diyarbakır from 2011 to 2020: The Impact of Migration and Epidemiological Trends
348	Abdul Mannan Mustafa	HIV through the mind of people unknowingly living among HIV patients; KAP study about HIV in slum area of Pakistan
500	Jonathan Nkalubo	Factors associated with readiness to start antiretroviral therapy (ART) among young people (15-24 years) at four HIV clinics in Mulago Hospital, Uganda
625	Elif Türkmen	Effectıveness Of Fecal Mıcrobıota Transplantatıon In Chıldren Wıth Inflammatory Bowel Dısease
677	Alfonso J. Rodriguez-Morales	Relationships between morbidity from Mpox and international tourism globally during 2022-2024 epidemics

Abstract	Presenter	Abstract Title
581	Evangelos J. Giamarellos Bourboulis	Clarithromycin adjunct treatment leads to substantial financial savings in community-acquired pneumonia: sub-analysis of the ACCESS trial
367	Luca Mezzadri	Comparison of meropenem-vaborbactam with ceftazidime-avibactam in the treatment of carbapenem-resistant Enterobacterales infections
530	Sohayeb Mohamed Ayoub	The Role of Students in Improving Patient Safety: An Integrative Approach
649	Nofri Rahmadika	Altered Interferon Responses in Tuberculosis Patients with Type II Diabetes: Implications for Increased Disease Susceptibility
372	Matthijs S Berends	Impact of Pre-Existing Comorbidities and Multimorbidities, Demography and Viral Variants on Post-Acute Sequelae of COVID-19 (‘Long COVID’) in Dutch Primary Care: A Retrospective Cohort Study
470	Meltem Ayaş	The investigation of the effectiveness of TK medium in determining primary anti-tuberculosis drug susceptibilities of Mycobacterium tuberculosis and a newly developed pyrazinamide susceptibility test
303	Emine Alp	The Effect of Training and Monitoring of Environmental Cleaning on The Rates of Intensive Care Unit Acquired Infections in A University Hospital
623	Reham Khedr	Successful management of pediatric patients with low-risk febrile neutropenia using a clinical care pathway in Egypt
195	Shinya Tsuzuki	Antimicrobial use for influenza-like illnesses in Nha Trang, Vietnam

Abstract	Presenter	Abstract Title
182	Reshma Silvester	A peek into hospital poo: Tracking pathogens and antimicrobial resistance
298	Shakeel Mowlaboccus	Genomic characterisation of vancomycin variable Enterococcus faecium causing bacteraemia in Australia
364	Huynh Ngoc Tram Vo	Genomic features of carbapenem-resistant Klebsiella pneumoniae isolated in French Polynesia and description of a novel transposon Tn7722 responsible for NDM-1 dissemination
660	Huda Ahmed	Distribution of Minimum Inhibitory Concentrations and Resistance-associated Gene Mutations in Multidrug-resistant Mycobacterium tuberculosis Strains from Southern Türkiye: Insights on Bedaquiline, Delamanid, and Linezolid
79	Igor Mokrousov	Genetics of mycobacterial adaptation to selective pressure of antituberculous compounds dissected at the in vitro and in vivo levels
652	Şevval Arduç Tok	Ceftazidim-avibactam susceptibility of carbapenemase producing enterobacterales in an oxa-48 endemic area
386	Neşe İnal	In-Vitro Antimicrobial Susceptibility Results of Brucella Species in Eastern Türkiye
692	Maryam Taghizadeh-Ghehi	Pattern of antibiotic use over two decades in Iran: a national level assessment based on WHO AWaRe classification from 2000 to 2019
191	Tuba Sena Karacesme	Potential Drug Interactions With Antibiotics On Intensive Care Units: A Retrospective Cross-Sectional Study

TOPICS	EXPERTS
Welcoming and Introduction	Prof. Murat Akova Chairman
Nosocomial Pneumonia & Early Antimicrobial Therapy	Prof. Önder Ergönül
Sepsis: Strategies for Rapid Diagnosis & Management	Prof. İlker Devrim
Panel Discussion (Q&A)

Time	Session title	Presenter
11:45–11:55	Welcome and introduction	Serhat Ünal (Turkey)
11:55–12:10	Keeping an eye on AMR: applying surveillance data to clinical practice	Rafael Cantón (Spain)
12:10–12:20	Panel discussion	All
12:20–12:35	Using real-world data to drive treatment success	Vu Do (Vietnam)
12:35–12:45	Panel discussion	All
12:45–13:00	Optimising dosing to improve patient outcomes and manage AMR	Balaji Veeraraghavan (India)
13:00–13:05	Panel discussion	All
13:05–13:15	Concluding remarks	Serhat Ünal (Turkey)

Time	Speakers
12:00-12:05	Co-Chairs	Opening Remarks
12:05- 12:30	Dr. Meral Akcay	Influenza beyond flu!
12:30-13:00	Dr. Alireza Mafi	Protection beyond flu!
13:00-13:30	Discussion and Q&A Session	All